期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 12, 期 8, 页码 1077-1081出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2014.0105
关键词
-
类别
资金
- Pfizer Inc.
- New Link Genetics, Inc.
- Astex Pharmaceuticals, Inc.
- Amgen Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4, leading to enhanced T-cell activation and proliferation, is associated with improved overall survival in melanoma. Its use can result in immune-related adverse events, the most common of which are skin rash, diarrhea, and colitis. Ipilimumab-induced hypophysitis is uncommon, mostly involves anterior pituitary, and is associated with abnormalities in pituitary MRI, whereas uveitis has been rarely reported. These immunerelated adverse events occur during therapy. This report describes a patient who developed uveitis and hypophysitis involving both anterior and posterior pituitary, without MRI findings more than 3 weeks after the fourth dose of ipilimumab. This case illustrates the unusual presentation of and diagnostic challenges associated with ipilimumab-induced immune-related adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据